Tertius News is an AI-native newsroom: an AI model reads the linked source articles below and extracts what each outlet reported, so you can compare their coverage side by side. How this works →

Australian regulator TGA warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic

Australia's Therapeutic Goods Administration has issued a new safety warning linking GLP-1-based medications—including Ozempic and Mounjaro—to a rare but severe eye disorder that can lead to blindness, after 36 cases were reported nationally.

By Tertius News AI Desk 2 outlets · 2 articles Version 1 Coverage Jul 24, 2026 Published Aug 14

Australia’s medicines regulator warns of rare eye disorder linked to weight-loss and diabetes drugs

Australia’s medicines regulator has issued a formal safety warning linking a class of drugs used to treat type 2 diabetes and obesity to a rare but potentially blinding eye condition.

The Therapeutic Goods Administration (TGA) said it had identified 36 cases of non-arteritic anterior ischaemic optic neuropathy (NAION) in Australia associated with glucagon-like peptide-1 (GLP-1) receptor agonists — the class of medicines marketed under brand names including Ozempic, Wegovy, Mounjaro, Trulicity and Saxenda.

NAION is caused by a reduction in blood flow to the optic nerve and may result in permanent visual impairment. According to the regulator, no treatment has been shown to improve visual outcomes once the condition develops.

The warning follows a study published in a peer-reviewed medical journal in 2024 that raised concerns about a possible link between the drugs and the condition, according to ABC Australia. The regulator said it had conducted its own independent assessment of the evidence since then.

The affected medicines — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), dulaglutide (Trulicity) and liraglutide (Saxenda) — are used to treat type 2 diabetes and, in some cases, obesity. The TGA’s warning said the products had the potential to cause NAION, a condition in which reduced blood flow to the optic nerve can lead to sudden vision loss.

According to the regulator, NAION may result in permanent visual impairment, and there is no evidence of any treatment that can restore visual acuity once the condition develops.

Key claims

The TGA linked 36 cases of NAION to GLP-1 receptor agonists, as reported by ABC Australia and The Guardian.
The affected medications include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), dulaglutide (Trulicity), and liraglutide (Saxenda), according to both outlets.
Product information documents for Australian patients have been updated to reflect the new warning, and patients are advised to seek urgent medical attention if they experience sudden or partial vision loss.
The TGA does not recommend stopping treatment without consulting a doctor, and has not introduced new restrictions on prescriptions.
Prof. Helen Danesh-Meyer of the Royal Australian and New Zealand College of Ophthalmologists cautioned that NAION remains a very rare condition, and that for many patients the benefits of continuing treatment may outweigh the risks.
The TGA said it first became aware of the potential link in 2024, following a study published in a peer-reviewed medical journal, and said further evidence has since been closely monitored.
The World Health Organisation has likewise issued a warning about the risk of NAION from semaglutide medicines, and the European Medicines Agency has recommended updating product information, as reported by ABC Australia.

Key claims

The TGA’s warning covers type 2 diabetes and obesity treatments including Ozempic and Mounjaro, with 36 reported cases of NAION in Australia.
NAION is a rare condition caused by reduced blood flow to the optic nerve that can lead to permanent vision loss, with no proven treatment to restore sight once it develops.
The TGA advises patients not to stop their medication without first consulting a doctor.
The World Health Organisation and the European Medicines Agency have separately signalled concern about the risk of NAION from GLP-1 medicines.

How each outlet told it

ABC Australia as of Jul 24, 2026, 1:45 AM UTC

Framing: Medicines regulator issues new safety warning for GLP-1-based drugs — Informative and cautionary

Facts Included:

The TGA issued a new safety warning for GLP-1-based drugs
The warning covers several glucagon-like peptide-1 (GLP-1) receptor agonists
36 cases of NAION were reported on the national database of adverse events
The World Health Organisation issued a warning about the risk of NAION from semaglutide medicines
The European Medicines Agency (EMA) recommended updating product information

Read the source article →

The Guardian — World as of Jul 24, 2026, 7:15 AM UTC

Framing: Warning over potential eye disorder from diabetes and obesity treatments — Informative and cautionary

Facts Included:

The Therapeutic Goods Administration (TGA) issued warnings for several type 2 diabetes and obesity-related treatments
36 cases of non-arteritic anterior ischaemic optic neuropathy (NAION) were linked to GLP-1 RA medicines
The TGA updated product information documents for Australians
Patients are urged to seek urgent medical attention if they experience sudden vision loss
The TGA does not recommend stopping treatment without consulting a doctor

Read the source article →

What was claimed, and who backed it

Each row is one claim, attributed to the outlet whose wording states it most clearly. Confidence rates how directly the source text states the claim — explicit and unhedged rates high; hedged, pieced-together, or internally inconsistent statements rate lower. It does not measure whether the claim is true. Status counts the distinct outlets we found asserting it — so a single-source claim can still show high confidence, and a multi-source claim can show medium. Every one of those outlets is named beside the status, so you can check the count against the list. For claims extracted before we began storing that list, the row says so: it names the outlet the claim is quoted from and states that we have not recorded which outlets backed it. Outlets wrote at different times, so a figure that evolves — a casualty count, for example — can legitimately differ between rows; check the "as of" time next to each claim's source.

Claim	Confidence	Status
ClaimThe Therapeutic Goods Administration (TGA) issued warnings for several type 2 diabetes and obesity-related treatments, including Ozempic and Mounjaro, over the potential to cause a rare but severe eye disorder that could lead to blindness.	ConfidenceHigh	StatusMulti-source quoted from The Guardian — World as of Jul 24, 2026, 7:15 AM UTC the outlets behind this status were not recorded for this claim
Claim36 cases of non-arteritic anterior ischaemic optic neuropathy (NAION) were linked to GLP-1 RA medicines.	ConfidenceHigh	StatusMulti-source quoted from The Guardian — World as of Jul 24, 2026, 7:15 AM UTC the outlets behind this status were not recorded for this claim
ClaimThe TGA updated product information documents for Australians and patients prescribed the drugs are urged to seek urgent medical attention if they experience sudden vision loss.	ConfidenceHigh	StatusSingle-source via The Guardian — World as of Jul 24, 2026, 7:15 AM UTC
ClaimThe TGA does not recommend stopping treatment without consulting a doctor.	ConfidenceHigh	StatusSingle-source via The Guardian — World as of Jul 24, 2026, 7:15 AM UTC
ClaimThe World Health Organisation issued a warning about the risk of NAION from semaglutide medicines.	ConfidenceHigh	StatusSingle-source via ABC Australia as of Jul 24, 2026, 1:45 AM UTC
ClaimThe European Medicines Agency (EMA) recommended updating product information.	ConfidenceHigh	StatusSingle-source via ABC Australia as of Jul 24, 2026, 1:45 AM UTC
ClaimNAION potentially affects up to 1 in 10,000 users.	ConfidenceHigh	StatusSingle-source via ABC Australia as of Jul 24, 2026, 1:45 AM UTC

Transparency & Audit Trail

2 outlets · 2 articles consulted: ABC Australia, The Guardian — World 7 claims extracted Version 1 Written 2026-08-14